synarin 25 mg ml nasal spray - search results

Singapore - English - HSA (Health Sciences Authority)

synagis sterile powder for injection 100 mgvial

abbvie pte. ltd. - palivizumab - injection, powder, for solution - 100 mg/vial (100mg/ml) - palivizumab 100 mg/vial (100mg/ml)

Canada - English - Health Canada

synagis powder for solution

abbvie corporation - palivizumab - powder for solution - 50mg - palivizumab 50mg - monoclonal antibodies

Canada - English - Health Canada

synagis powder for solution

abbvie corporation - palivizumab - powder for solution - 100mg - palivizumab 100mg - monoclonal antibodies

United States - English - NLM (National Library of Medicine)

synagis- palivizumab injection, solution

medimmune, llc - palivizumab (unii: dq448mw7ks) (palivizumab - unii:dq448mw7ks) - palivizumab 100 mg in 1 ml - 1 indications and usage synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv) in pediatric patients: limitations of use: the safety and efficacy of synagis have not been established for treatment of rsv disease [see warnings and precautions (5.4)] . synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to synagis [see warnings and precautions (5.1)] . risk summary synagis is not indicated for use in females of reproductive potential. risk summary synagis is not indicated for use in females of reproductive potential. the safety and effectiveness of synagis in children older than 24 months of age at the start of dosing have not been established [see clinical studies (14) ] .